Bayer stock at EUR 57.26, up 1.13% before Xetra open
Published on 11/10/2026 at 08:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey developments for Bayer
- The FDA approved SUNHARBO, Bayer's asundexian, for secondary stroke prevention in combination with antiplatelet therapy.
- The Phase 3 OCEANIC-STROKE trial showed a 26 percent reduction in ischemic stroke versus placebo.
- Bayer expects U.S. shipments to begin in mid-to-late November, while European and Japanese reviews continue.
Bayer stock traded at EUR 57.26 on Lang & Schwarz at 08:36 CET on Tuesday, November 10, 2026, 1.13 percent above the Xetra close of Monday, November 9, 2026.
Bayer said the U.S. Food and Drug Administration approved SUNHARBO, the company's once-daily asundexian tablet, for reducing the risk of stroke in adults with a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack. The medicine is used in combination with antiplatelet therapy. The approval makes SUNHARBO the first Factor XIa inhibitor approved in the United States, according to Business Wire.
New drug adds to pharma momentum
The approval was based on the Phase 3 OCEANIC-STROKE study, which enrolled 12,327 patients. Ischemic strokes occurred in 6.2 percent of patients receiving SUNHARBO and 8.4 percent of those receiving placebo, a relative reduction of 26 percent. Major bleeding rates were similar between the two groups, while gastrointestinal bleeding was higher with SUNHARBO.
Bayer expects U.S. shipments to start in mid-to-late November. SUNHARBO is also under review by the European Medicines Agency and Japan's Ministry of Health, Labour and Welfare. The drug was approved in China on October 26, 2026. The launch gives Bayer a new commercial opportunity in Pharmaceuticals, although the product's uptake, reimbursement and safety profile will shape its earnings contribution.
German equities will provide the broader market backdrop through the DAX.
